Zobrazeno 1 - 10 of 52 pro vyhledávání: '"Schwab, RB"'
1
Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients
Autor: Schwaederle, M, Krishnamurthy, N, Daniels, GA, Piccioni, DE, Kesari, S, Fanta, PT, Schwab, RB, Patel, SP, Parker, BA, Kurzrock, R
Publikováno v: Cancer, vol 124, iss 6
Schwaederle, M; Krishnamurthy, N; Daniels, GA; Piccioni, DE; Kesari, S; Fanta, PT; et al.(2018). Telomerase Reverse Transcriptase Promoter Alterations Across Cancer Types as Detected by Next-Generation Sequencing: A Clinical and Molecular Analysis of 423 Patients. CANCER, 124(6), 1288-1296. doi: 10.1002/cncr.31175. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/9ff896np
BACKGROUND:Telomerase reverse transcriptase (TERT) promoter mutations that may affect telomerase activity have recently been described in human malignancies. The purpose of this study was to investigate the clinical correlates of TERT promoter abnorm
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::0e301dd4452de538a055cb4d6f51282c
https://escholarship.org/uc/item/9ff896np
Zobrazit plný text záznamu
2
A window-of-opportunity biomarker study of etodolac in resectable breast cancer
Autor: Schwab, RB, Kato, S, Crain, B, Pu, M, Messer, K, Weidner, N, Blair, S, Wallace, AM, Carson, DA, Parker, BA
Publikováno v: Cancer medicine, vol 4, iss 10
Schwab, RB; Kato, S; Crain, B; Pu, M; Messer, K; Weidner, N; et al.(2015). A window-of-opportunity biomarker study of etodolac in resectable breast cancer. CANCER MEDICINE, 4(10), 1583-1588. doi: 10.1002/cam4.512. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/0kp9674s
Observational data show that nonsteroidal anti-inflammatory drug (NSAID) use is associated with a lower rate of breast cancer. We evaluated the effect of etodolac, an FDA-approved NSAID reported to inhibit cyclooxygenase (COX) enzymes and the retinoi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::5680ec318d0f3504384288815b59b080
https://escholarship.org/uc/item/0kp9674s
Zobrazit plný text záznamu
3
Impact of a clinical care online intake form in a breast care clinic
Autor: Messer, K, Pierce, JP, Madlensky, L, Cadmus, L, Patterson, RE, Chase, PW, Faerber, S, Schwab, RB, Blair, S, Wallace, AM, Parker, BA
Publikováno v: Messer, K; Pierce, JP; Madlensky, L; Cadmus, L; Patterson, RE; Chase, PW; et al.(2013). Impact of a clinical care online intake form in a breast care clinic.. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/77h0j61t
137 Background: An online self-reported clinical care intake form was provided to new surgery patients of the Moores UCSD Breast Care Clinic, as part of a pilot project in collaboration with the University of California Athena Breast Health Network.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::31116d8331c67df8662141a3243aece2
http://www.escholarship.org/uc/item/77h0j61t
Zobrazit plný text záznamu
4
Use of clinical care registries to facilitate research study recruitment
Autor: Layton, TM, Chen, T, Nandigam, V, Abihider, K, Chase, PW, Pierce, JP, Madlensky, L, Cadmus, L, Patterson, RE, Faerber, S, Schwab, RB, Blair, S, Wallace, AM, Ojeda-Fournier, H, Parker, BA
Publikováno v: Layton, TM; Chen, T; Nandigam, V; Abihider, K; Chase, PW; Pierce, JP; et al.(2013). Use of clinical care registries to facilitate research study recruitment.. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/2gb629gv
129 Background: We developed IRB-approved secure research registries for our Breast Imaging and Breast Care Clinics at Moores UC San Diego Cancer Center, as part of the UC statewide Athena Breast Health Network. Our clinical care registries securely
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::6027ea9df53a4668f04842d9c58a6758
http://www.escholarship.org/uc/item/2gb629gv
Zobrazit plný text záznamu
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
7
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer.
Autor: Shatsky RA; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA.; Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA., Batra-Sharma H; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA.; Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA., Helsten T; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA.; Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA., Schwab RB; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA.; Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA., Pittman EI; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA., Pu M; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA., Weihe E; Department of Radiology, University of California San Diego, La Jolla, San Diego, CA, USA., Ghia EM; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA.; Center for Novel Therapeutics, University of California San Diego, La Jolla, San Diego, CA, USA., Rassenti LZ; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA.; Center for Novel Therapeutics, University of California San Diego, La Jolla, San Diego, CA, USA., Molinolo A; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA., Cabrera B; University of California San Diego California Institute for Regenerative Medicine Alpha Clinic, La Jolla, San Diego, CA, USA., Breitmeyer JB; Oncternal Therapeutics, Inc., San Diego, CA, USA., Widhopf Ii GF; Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA.; Center for Novel Therapeutics, University of California San Diego, La Jolla, San Diego, CA, USA., Messer K; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA.; Herbert Wertheim School of Public Health, University of California San Diego, La Jolla, San Diego, CA, USA., Jamieson C; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA.; Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA.; University of California San Diego California Institute for Regenerative Medicine Alpha Clinic, La Jolla, San Diego, CA, USA.; Sanford Stem Cell Institute, University of California San Diego, La Jolla, San Diego, CA, USA., Kipps TJ; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA.; Center for Novel Therapeutics, University of California San Diego, La Jolla, San Diego, CA, USA., Parker BA; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA. baparker@health.ucsd.edu.; Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA. baparker@health.ucsd.edu.
Publikováno v: Breast cancer research : BCR [Breast Cancer Res] 2024 Mar 13; Vol. 26 (1), pp. 46. Date of Electronic Publication: 2024 Mar 13.
Zobrazit plný text záznamu
8
Akademický článek
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer.
Autor: Shatsky RA; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA.; Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA., Batra-Sharma H; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA.; Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA., Helsten T; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA.; Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA., Schwab RB; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA.; Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA., Pittman EI; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA., Pu M; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA., Weihe E; Department of Radiology, University of California San Diego, La Jolla, San Diego, CA, USA., Ghia EM; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA.; Center for Novel Therapeutics, University of California San Diego, La Jolla, San Diego, CA, USA., Rassenti LZ; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA.; Center for Novel Therapeutics, University of California San Diego, La Jolla, San Diego, CA, USA., Molinolo A; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA., Cabrera B; University of California San Diego California Institute for Regenerative Medicine Alpha Clinic, La Jolla, San Diego, CA, USA., Breitmeyer JB; Oncternal Therapeutics, Inc., San Diego, CA, USA., Widhopf GF 2nd; Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA.; Center for Novel Therapeutics, University of California San Diego, La Jolla, San Diego, CA, USA., Messer K; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA.; Herbert Wertheim School of Public Health, University of California San Diego, La Jolla, San Diego, CA, USA., Jamieson C; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA.; Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA.; University of California San Diego California Institute for Regenerative Medicine Alpha Clinic, La Jolla, San Diego, CA, USA.; Sanford Stem Cell Institute, University of California San Diego, La Jolla, San Diego, CA, USA., Kipps TJ; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA.; Center for Novel Therapeutics, University of California San Diego, La Jolla, San Diego, CA, USA., Parker BA; Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA. baparker@health.ucsd.edu.; Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA. baparker@health.ucsd.edu.
Publikováno v: Breast cancer research : BCR [Breast Cancer Res] 2024 Feb 26; Vol. 26 (1), pp. 32. Date of Electronic Publication: 2024 Feb 26.
Zobrazit plný text záznamu
9
Akademický článek
Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.
Autor: Parker BA; Department of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA. baparker@health.ucsd.edu., Shatsky RA; Department of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA., Schwab RB; Department of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA., Wallace AM; Department of Surgery and Moores Cancer Center, University of California San Diego, La Jolla, CA, USA., Wolf DM; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA., Hirst GL; Department of Surgery, University of California San Francisco, San Francisco, CA, USA., Brown-Swigart L; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA., Esserman LJ; Department of Surgery, University of California San Francisco, San Francisco, CA, USA., van 't Veer LJ; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA., Ghia EM; Department of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.; Center for Novel Therapeutics, University of California San Diego, La Jolla, CA, USA., Yau C; Department of Surgery, University of California San Francisco, San Francisco, CA, USA., Kipps TJ; Department of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.; Center for Novel Therapeutics, University of California San Diego, La Jolla, CA, USA.
Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2023 Jun; Vol. 199 (2), pp. 281-291. Date of Electronic Publication: 2023 Apr 08.
Zobrazit plný text záznamu
10
Akademický článek
Cancer-cell-secreted extracellular vesicles suppress insulin secretion through miR-122 to impair systemic glucose homeostasis and contribute to tumour growth.
Autor: Cao M; Department of Pathology, University of California, San Diego, La Jolla, CA, USA., Isaac R; Department of Medicine, University of California, San Diego, La Jolla, CA, USA., Yan W; Department of Pathology, University of California, San Diego, La Jolla, CA, USA., Ruan X; Department of Pathology, University of California, San Diego, La Jolla, CA, USA., Jiang L; Department of Pathology, University of California, San Diego, La Jolla, CA, USA., Wan Y; Department of Pathology, University of California, San Diego, La Jolla, CA, USA., Wang J; Department of Pathology, University of California, San Diego, La Jolla, CA, USA., Wang E; Department of Pathology, University of California, San Diego, La Jolla, CA, USA., Caron C; Department of Pathology, University of California, San Diego, La Jolla, CA, USA., Neben S; Regulus Therapeutics Inc., San Diego, CA, USA., Drygin D; Regulus Therapeutics Inc., San Diego, CA, USA., Pizzo DP; Department of Pathology, University of California, San Diego, La Jolla, CA, USA., Wu X; Department of Molecular and Cellular Biology, City of Hope, Duarte, CA, USA., Liu X; Department of Pathology, University of California, San Diego, La Jolla, CA, USA., Chin AR; Department of Pathology, University of California, San Diego, La Jolla, CA, USA., Fong MY; Department of Pathology, University of California, San Diego, La Jolla, CA, USA., Gao Z; Department of Chemistry, University of California, Riverside, Riverside, CA, USA., Guo K; Department of Chemistry, University of California, Riverside, Riverside, CA, USA., Fadare O; Department of Pathology, University of California, San Diego, La Jolla, CA, USA., Schwab RB; Department of Medicine, University of California, San Diego, La Jolla, CA, USA., Yuan Y; Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA, USA., Yost SE; Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA, USA., Mortimer J; Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA, USA., Zhong W; Department of Chemistry, University of California, Riverside, Riverside, CA, USA., Ying W; Department of Medicine, University of California, San Diego, La Jolla, CA, USA., Bui JD; Department of Pathology, University of California, San Diego, La Jolla, CA, USA., Sears DD; Department of Medicine, University of California, San Diego, La Jolla, CA, USA.; College of Health Solutions, Arizona State University, Phoenix, AZ, USA.; Department of Family Medicine, University of California, San Diego, La Jolla, CA, USA.; Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA., Olefsky JM; Department of Medicine, University of California, San Diego, La Jolla, CA, USA., Wang SE; Department of Pathology, University of California, San Diego, La Jolla, CA, USA. emilywang@ucsd.edu.; Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA. emilywang@ucsd.edu.
Publikováno v: Nature cell biology [Nat Cell Biol] 2022 Jun; Vol. 24 (6), pp. 954-967. Date of Electronic Publication: 2022 May 30.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje